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Abstract: The rapid advent of technology in recent years has resulted 
in a substantial increase in our knowledge of the molecular underpin-
nings of thymic epithelial tumors. In addition to previously described 
chromosomal aberrations and alterations in DNA methylation, genome 
sequencing has helped unravel hitherto unknown mutations in these 
tumors. Attempts are also being made to develop gene signatures to help 
in the identification of patients likely to benefit from adjuvant therapy. 
Some of the recently identified genetic alterations have the potential 
to serve as targets for biological therapy, thus opening newer avenues 
for treatment of thymic epithelial tumors and increasing the number of 
effective options for treatment of recurrent or refractory disease.
Key Words: Thymoma, Thymic carcinoma, Methylation, Chromosomal 
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Thymic epithelial tumors (TETs) are rare mediastinal cancers that have traditionally been treated using a mul-
timodality approach consisting of surgery, radiotherapy, and 
platinum-based chemotherapy.1 Effective treatment options 
are limited for patients with recurrent disease. The World 
Health Organization (WHO) classification is the most widely 
used system for the histological classification of TETs.2 Based 
on thymic epithelial cell morphology, the degree of thymocyte 
involvement and the extent of epithelial atypia TETs are clas-
sified into the following subtypes: A, AB, B1, B2, B3, and C.
Efforts such as The Cancer Genome Atlas (TCGA) 
research network have helped in providing a deep understanding 
of the molecular alterations associated with a variety of tumors.3–7 
In comparison, until recently, scant information was available 
on genomic changes associated with TETs. Major challenges in 
obtaining genetic data still exist, especially from the more com-
mon thymoma subtypes (AB, B1, and B2) due to the presence 
of a significant number of non-neoplastic thymocytes. The latter 
typically outnumber and tightly intermingle with the neoplas-
tic epithelial cells and largely preclude classical or array-based 
comparative genomic hybridization (CGH) approaches except 
in rare cases in which epithelial content is unusually high or in 
which thymocytes can be removed through short-term cell cul-
ture of neoplastic epithelial cells.8–11 Fluorescence in situ hybrid-
ization analyses have been sparse as well.8,12,13 However, with 
the advent of newer and more sensitive techniques in molecular 
biology (e.g., next generation sequencing) and bioinformatics, 
there has been and will be an incremental increase in the avail-
ability of high-quality data that has helped in expanding our 
understanding of the molecular pathogenesis of these diseases. 
Development of newer therapies based on an understanding of 
genomic alterations could potentially revolutionize treatment of 
TETs and result in an improvement in clinical outcomes. This 
review provides an overview of genetic alterations associated 
with TETs with a focus on recent discoveries that could have an 
impact on the management of thymic cancers.
CHROMOSOMAL ABNORMALITIES
Copy number (CN) gains and losses of various chromo-
somes have been well described in TETs, and the frequency 
of these changes is higher in the more aggressive histological 
subtypes. Based on the pattern of chromosomal changes, TETs 
can be clustered into various groups, demonstrating a correla-
tion between genetic findings and WHO-based histology, with 
overlapping alterations between type AB and B2 thymoma, 
B2 and B3 thymoma, and B3 thymomas and thymic carcino-
mas.8–11,14 In short, 6q25.2–25.3 loss is observed in all sub-
types except B1 thymomas (a paucity of B1 thymomas among 
cases analyzed might have had a bearing on this result); 1q 
gains are common in type B2, B3 thymomas and thymic car-
cinomas; in addition, thymic carcinomas present with 1q, 4, 5, 
7, 8, 9q, 12, 15, 17q, 18, 20 gains, and 3p, 6, 6p23, 9p, 13q, 
14, 16q, 17p losses.9–11,14 The biological significance of these 
changes is yet to be determined in the vast majority of cases. 
However, it is known that the 6p23 region encompasses the 
FOXC1 tumor suppressor gene, and chromosomal loss is cor-
related with lower protein expression. Patients with FOXC1-
negative tumors had a shorter time to progression and a trend 
for a shorter disease-related survival.15
ALTERATIONS IN DNA METHYLATION
Silencing of tumor suppressor genes such as FHIT, 
MLH1, and E-cad by promoter hypermethylation has been 
described in TETs.16 These changes along with DNA hypo-
methylation have been correlated with Masaoka stage and 
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WHO subtype of the TET. Other genes affected by aber-
rant methylation include DAP-K, p16, MGMT, and HPP1.17 
MGMT methylation and loss of its protein expression has 
been reported to be significantly more frequent in thymic car-
cinoma than in thymoma (74% versus 29%) and in advanced 
TETs (stages III/IV) compared with early stage tumors (stages 
I/II).18 Methylation of the promoter region of CDKN2 has 
been observed in up to 14% of thymomas and 25% of thymic 
carcinomas.19 Immunohistochemical analysis of 132 TETs 
demonstrated CN loss of CDKN2A accompanied by lack 
of expression of its related protein p16INK4 and identified 
tumors with poor prognosis.20
A deeper understanding of alterations in DNA methyla-
tion can have important therapeutic implications. For example, 
MGMT hypermethylation is associated with a greater degree 
of sensitivity to alkylating agents.21 Dysregulation of the 
cyclin-dependant kinase pathway can potentially be offset by 
using cyclin-dependent kinase inhibitors such as milciclib. An 
ongoing phase II study is evaluating the efficacy of milciclib 
in thymic carcinoma (NCT01011439). Forty-three patients 
have been enrolled and treated to date including 26 patients 
with thymic carcinoma and nine patients with B3 thymoma. 
Of 30 evaluable patients, 14 have met the prespecified primary 
end point of progression-free survival at 3 months (PFS-3 rate 




In an effort to overcome the limitations associated with 
traditional histological classification of TETs, efforts have 
been made to correlate the results of gene expression deter-
mined by whole genome gene expression analysis with clinical 
parameters such as stage of disease. Badve et al.23 conducted 
a retrospective analysis in 34 patients with type AB and B thy-
moma using RNA extracted from fresh frozen tumors. Ten of 
34 patients had received chemotherapy and eight patients had 
received radiation therapy. Eight patients were known to have 
metastatic disease either at diagnosis or developed it during the 
follow-up period. In addition, although all patients underwent 
surgery with curative intent, eight patients developed disease 
relapse during the follow-up period. After gene expression 
analysis using Partek Genomics Suite and Ingenuity Pathways 
Analysis, four molecular clusters of tumors were identified 
by unsupervised cluster analysis of 8260 genes that showed 
unique gene expression profiles. Supervised cluster analysis 
using 15 genes with the highest positive and negative fold 
changes helped in the identification of three clusters of his-
tologically heterogeneous tumors. Analysis of clinical param-
eters such as stage of disease and presence of metastases did 
not show a correlation with either histological subtype or the 
newly identified gene expression clusters. However, ingenuity 
pathway analysis resulted in the identification of differentially 
expressed genes in patients with or without metastatic dis-
ease. In tumors obtained from the metastasis-positive group, 
there was a sixfold and threefold increase in the expression 
of AKR1B10 and JPH1, respectively, whereas expression 
of COL1A1 was decreased 13-fold. This is the first study to 
attempt a correlation between expression of individual genes 
and clinical factors in TETs. Validation of data obtained from 
this study has the potential to identify newer therapeutics tar-
gets such as AKR1B10.24
Gene Signatures
Traditional prognostic factors associated with TETs 
have included Masaoka stage, histological subtype, and the 
completeness of surgical resection.25 Most attempts to identify 
prognostic and predictive biomarkers have focused on correla-
tions with the stage and histological subtype of disease.9,26–28 
The first study to attempt a correlation between gene expres-
sion and the risk of development of metastases was reported 
in 2013.29 In a retrospective study using archival samples of 
thymomas from multiple institutions, gene expression levels 
were used to categorize tumors into two groups based on the 
probability of developing metastases. This study included 
111 cases of thymoma (36 in the training set and 75 in the 
validation set). Based on the prediction analysis of microar-
rays (PAMs), 19 differentially expressed genes and four refer-
ence genes were selected for quantitative reverse transcriptase 
polymerase chain reaction analysis. The primary end point of 
the study was to determine whether a gene signature could 
predict 5- and 10-year metastasis-free survival (MFS). A nine-
gene signature was identified that could identify patients at 
low- and high-risk for metastasis with 5- and 10-year MFS of 
77% and 26% (p = 0.0047) and 97% and 30% (p = 0.0004) 
in the training and validation sets, respectively. In univariate 
Cox regression analysis, the nine-gene signature was a strong 
predictor of the development of metastasis with a hazard ratio 
(HR) of 8.33 (95% CI = 1.99–34.9; p = 0.004) compared with 
a HR of 2.51 (95% CI = 1.22–5.15; p = 0.012) for presence 
of residual disease and a HR of 2.09 (95% CI = 0.95–4.59; 
p = 0.067) for Masaoka stage. In multivariate analysis, the 
nine-gene signature was the only independent predictor of the 
risk of developing metastasis (HR 5.26, 95% CI = 1.12–24.8; 
p = 0.036). Genes with increased expression in tumors with 
a higher metastatic potential included AKR1B10, JPH1, and 
NGB. Conversely, genes with decreased expression in tumors 
with high metastatic potential included DACT3, SLC9A2, 
PDGFRL, FCGBP, PRRX1, and SERPINF1.
The practical implications of development of prognos-
tic biomarkers such as the gene signature illustrated above 
are the identification of patients at high risk for recurrence 
who might benefit from administration of appropriate adju-
vant therapy and the potential to identify novel drug targets 
for patients at higher risk for development of unresectable, 
metastatic disease. However, significant challenges need to be 
overcome before widespread adoption of gene signatures in 
clinical practice, especially for rare diseases like TETs. These 
include the need for validation of results in a prospective set-
ting, a clear demonstration of benefit over widely used clini-
cal parameters such as Masaoka stage, histological subtype 
and completeness of resection, and the ease of performing the 
gene expression assay. Some of the limitations that might oth-
erwise preclude mass validation of a gene signature for TETs 
can be surmounted by performing prospective trials involving 
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multiple institutions or in a cooperative group setting to maxi-
mize accrual of cases.
Whole Genome and Transcriptome Sequencing
The first reported TET to be analyzed using whole 
genome and transcriptome sequencing involved a surgi-
cally resected stage IVA, B3 thymoma.30 In addition to 
well-described changes in gene CN, a number of previously 
unreported observations were made including a translocation 
involving chromosome 11 and the X chromosome, t(11;X), 
and mutations in BCOR, FBN3, PCNXL3, PHF15, SFXN3, 
SRGAP1, VN1R5, and WDR70. The pathogenic role of FBN3, 
PCNXL3, SFXN3, SRGAP1, VN1R5, and WDR70 is unclear. 
However, PHF15 belongs to the PHF protein family, several 
members of which affect chromatin-mediated gene regulation 
and BCOR is a corepressor of several transcription factors. 
The mutation rate of 0.72/Mb seen in this case (including sin-
gle nucleotide variations and insertions/deletions) was com-
parable with that observed in more aggressive malignancies 
such as breast cancer and myelogenous leukemia. However, 
no mutations were observed in well-characterized cancer 
genes. This report highlights the fact that TETs have a unique 
mutational profile that is not detectable by gene panels used 
for molecular profiling of common solid tumors, and strate-
gies such as whole exome sequencing might be better suited 
to identify recurrent mutations in this rare tumor type, some of 
which may represent targets for treatment.
IDENTIFICATION OF DRUG TARGETS
Initial experiences of the use of targeted therapy in 
TETs have been disappointing. The reasons for these negative 
results have become clear with the advent of technology and 
the relative ease of performing mutational analysis in recent 
years. However, a subset of patients with TETs do benefit from 
targeted therapy, highlighting the need to gain greater insight 
into TET biology to help select patients for targeted therapy. 
These concepts are illustrated by the following examples.
KIT overexpression is frequently observed in thy-
mic carcinomas (75–80%), whereas KIT gene mutations are 
found in less than 10% of cases.9,31 Based on the type of KIT 
mutation, TETs demonstrate varying degrees of sensitivity to 
tyrosine kinase inhibitors. In order of sensitivity to sunitinib 
and imatinib, these mutations include: W557R, V559A, and 
V560del (all on exon 11 and highly sensitive to sunitinib and 
imatinib); Y553N and D579del (both on exon 11 and highly 
sensitive to imatinib); E490K on exon 9 (highly sensitive to 
sunitinib and moderately sensitive to imatinib); H697Y on 
exon 14 (highly sensitive to sunitinib and low sensitivity to 
imatinib); L576P on exon 11 (moderate sensitivity to sunitinib 
and low sensitivity to imatinib); and D820E on exon 17 (resis-
tant to sunitinib and imatinib).1 The rarity and spectrum of KIT 
mutations in thymic carcinoma explains the lack of activity of 
imatinib in phase II trials where patient selection was based 
on histology (B3 thymomas and thymic carcinomas) or KIT 
staining by immunohistochemistry and not genotyping.32,33 A 
similar pattern of overexpression of epidermal growth factor 
receptor (EGFR) and a paucity of sensitizing mutations in the 
EGFR gene has been observed in TETs.31 Not surprisingly, 
clinical trials evaluating EGFR inhibitors have yielded disap-
pointing results.34,35
Despite these observations, a few recently completed 
clinical trials of targeted therapy in TETs have yielded prom-
ising results. The multikinase inhibitor, sunitinib, has been 
evaluated in a phase II clinical trial in TETs. Among 23 evalu-
able patients with thymic carcinoma, sunitinib demonstrated 
a response rate of 26% and disease control rate of 91%.36 
The response to sunitinib was independent of the mutational 
status of KIT and seems to be partly related to an antiangio-
genic effect. Cixutumumab, a monoclonal antibody–directed 
against the insulin-like growth factor-1 receptor, has been 
evaluated in a phase II trial and demonstrated a 89% disease 
control rate in patients with relapsed or refractory thymoma.37 
Results from selected clinical trials of targeted therapy for 
TETs are presented in Table 1.34–41
In the aforementioned trials, patient selection was not 
based on the presence of targetable mutations. Expression of 
potential drug targets such as the vascular endothelial growth 
factor receptor and the insulin-like growth factor 1-recep-
tor that could potentially explain the activity of drugs like 
sunitinib and cixutumumab are being evaluated in TETs 
(Table 2).12,13,42–50 Greater use of genomic analysis to optimize 
patient selection based on the presence of targetable mutations 
has the potential to improve upon the results obtained so far 
with targeted therapy.
Role of Newer Methods of Genomic and 
Integrative Analysis to Identify Drug Targets
Because strategies to identify genetic mutations often 
seen in other solid tumors have not yielded promising results 
for TETs, newer panels of tests need to be developed that 
focus on identifying genetic alterations that might be unique 
to TETs.
Recently, differentially expressed miRNAs have been 
identified in TETs. Upregulation of miR-21-5p, miR-34b-5p, 
and miR-141-3p, as well as down-regulation of miR-486-5p 
and miR-145-5p has been observed in TETs in comparison 
with normal tissue.51 miR-145-5p down-regulation is thought 
to lead to EGFR signaling pathway overexpression. miR-
128, miR-142-5p, and miR-181c-5p are also differentially 
expressed in thymoma versus thymic carcinoma. Interestingly, 
among the miRNAs down-regulated in thymic carcinoma, 
some putatively target BIRC3, SCYA20, and MYC.52 
Differential expression of antiapoptotic genes has also been 
identified in B3 thymoma and squamous cell carcinoma of the 
thymus. These results have raised the possibility of therapeu-
tic intervention with drugs targeting inhibitors of apoptosis 
and BIRC3.52 In another study, miR-515 overexpression was 
observed in type A-AB thymomas; this may result in PTEN 
inhibition, which could potentially be targeted by PIK3CA/
AKT inhibitors.53
Array CGH in 59 TETs reported recurrent CN gain of 
BCL2, providing further evidence for the role of an antiapop-
totic strategy as a major hallmark of TETs.20 Moreover, TET 
cell lines were reported to be sensitive to siRNA knockdown 
of the antiapoptotic molecules BCL2 and MCL1. Gx15-070, a 
pan-BCL2 inhibitor, induced autophagy-dependent necrosis in 
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TET cells through a mechanism involving mammalian target 
of rapamycin (mTOR) pathways, and inhibited TET xenograft 
growth. Hence, mTOR targeting may represent a clinically 
relevant approach for treatment of advanced TETs.54,55 Table 3 
summarizes selected molecular alterations in TETs.
IMPACT OF THE GENOMICS REVOLUTION AND 
LESSONS FOR CLINICAL PRACTICE
In view of the rarity of TETs, translation of preclinical 
observations into newer therapies poses unique challenges. 
One approach to validate the concept of personalized medi-
cine in thymic malignancies is the development of open-label, 
multicenter phase II trials using high-throughput genome anal-
ysis (multiplex mutation sequencing, CGH arrays, next gen-
eration sequencing) as a therapeutic decision tool to identify 
patients for targeted therapy directed against specific molecu-
lar alterations identified in their tumors. TETs have been inte-
grated into a few clinical trials using this approach such as 
the recently completed CUSTOM trial (NCT01306045), the 
first prospective study of molecular profiling to determine eli-
gibility for targeted therapy in patients with TETs.56 Tumors 
were analyzed for molecular changes including mutations in 
EGFR, KRAS, HRAS, NRAS, BRAF, PIK3CA, AKT, PTEN, 
ERBB2, KIT, and PDGFRA, amplification of HER2 or ALK 
translocations in a CLIA-certified laboratory, and patients 
were assigned to one of five treatment groups on the basis 
of these changes. This study showed that the genomic altera-
tions described above were uncommon in TETs and included 
HER2 amplification in 7.7% of samples analyzed, and a 
mutational frequency of 4.7% in HRAS and 1.4% in PIK3CA 
and EGFR genes. This trial confirms the uniqueness of the 
TABLE 1.  Selected Clinical Trials of Targeted Therapies for Thymic Epithelial Tumors
Intervention Evaluable Patients Responses




Gefitinib 26 1 4 NR 34
 Thymoma 19 NR NR NR
 Thymic carcinoma 7 NR NR NR
Erlotinib + bevacizumab 18 0 NR Not reached 35
 Thymoma 11 0 NR Not reached
 Thymic carcinoma 7 0 NR Not reached
Sunitinib 39 7 NR NR 36
 Thymoma 16 1 8.5a Not reached
 Thymic carcinoma 23 6 6.7a 16.3
Cixutumumab 49 5 8.2 16.2 37
 Thymoma 37 5 9.9 27.5
 Thymic carcinoma 12 0 1.7 8.4
Imatinib 15 0 3a Nor reached 38
 Thymoma 12 0 NRa NR
 Thymic carcinoma 3 0 NRa NR
Saracatinib 21 0 NRa NR 39
 Thymoma 14 NR 3.4a Not reached
 Thymic carcinoma 7 NR 1.4a Not reached
Belinostat 40 2 NR NR 40
 Thymoma 24 2 11.4 Not reached
 Thymic carcinoma 16 0 2.7 12.4
Everolimus 35 4 12.1a 24 41
 Thymoma 23 1 NRa NR








EGFR 13, 42, 43
  Amplification 20% 25%
  Overexpression 23% 67–100%
HER2 12, 44
  Amplification 6% 0–4%
  Overexpression 53–58%
KIT 45–47
  Overexpression 0–4% 46–86%
IGF-1R 48, 49
  Overexpression 14–43% 86–88%
VEGF 50
  Overexpression 32% 63%
IGF-1R, insulin-like growth factor-1 receptor.
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mutational profile of TETs and the inability of gene panels 
designed for other solid tumors to detect mutations in TETs 
that can help identify patients for targeted therapy. Another 
approach is to promote the enrolment of patients with refrac-
tory TETs in appropriate phase I trials, which may lead to 
the identification of new molecular pathways of therapeutic 
interest. For example, the mTOR pathway has emerged as 
a potential area of interest after tumor responses observed 
in phase I trials reported by several groups.54,55 In addition, 
disease stabilization as a result of treatment with the mTOR 
inhibitor, everolimus, in combination with somatostatin ana-
logs has been described in a case series of two patients with 
thymoma.57 An ongoing phase II clinical trial is evaluating 
the role of the mTOR inhibitor, everolimus, in patients with 
previously treated TETs (NCT02049047). Preliminary results 
show a disease control rate of 71%, median PFS of 12 months, 
and overall survival of 24 months.41 These novel approaches 
have the potential to help in the successful translation of the 
increasing volume of data generated by newer genomic tech-
nologies and help in the development of newer therapies for 
patients with TETs.
CONCLUSIONS
Rapid advances in technology have helped uncover 
novel genetic alterations in TETs and resulted in an increas-
ing recognition that TETs have a unique molecular profile 
compared with other solid tumors. These new discoveries 
have helped in gaining greater insight into thymic tumor biol-
ogy and have resulted in a steady increase in the identifica-
tion of molecular alterations that have the potential to serve 
as biomarkers or drug targets. Attempts should be made to 
incorporate these data into future clinical trials to help select 
patients for appropriate interventions with an aim to improve 
response to treatment and survival.
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